Decitabine, Methotrexate, L-asparaginase, Dexamethasone and Aclacinomycin protocol for patinets with relapsed and refractory T lynphoblastic lynphoma

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-14004114

Enrollment

Unknown

Registered

2014-01-05

Start date

2014-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T lynphoblastic lynphoma

Interventions

One cohort:Decitabine, Methotrexate, L-asparaginase, Dexamethasone and Aclacinomycin protocol

Eligibility

Sex/Gender

All

Age

14 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. T lymphoblastic lymphoma proved by pathology and immunohistology; 2. Ages 14~70 years; 3. Performance status as ECOG 0-2; 4. no combined with other tumors; 5. Expectation of life was over 3 months; 6. Voluntary participation and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients combined with any unstable systemic diseases; 3. Any conditions that the investigator regards to be not suitable for current study.

Design outcomes

Primary

Measure	Time frame
overall response rate;time to progress;one year and two year survival rate;overall survival;complete response rate;Grade 3/4 toxicitie;	—

Countries

China

Contacts

Public ContactMei Huang

Department of Hematology, Tongji Hospital of Huazhong University of Science and Technology

huangmei@medmail.com.cn+86 13545011174

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026